Matricaria chamomilla L. — One of the world's most studied medicinal plants, delivering validated anti-inflammatory, anxiolytic, and gastroprotective actions through a rich constellation of flavonoids, sesquiterpenes, and essential oil constituents.
German Chamomile is a small annual herb of the Asteraceae family, native to Europe and North Africa, now cultivated and naturalised worldwide. Its capitulate flower heads yield a characteristic deep-blue essential oil rich in chamazulene, bisabolol, and flavonoids — a phytochemical profile behind its well-documented anti-inflammatory, spasmolytic, and anxiolytic activities. The EMA has issued a positive herbal monograph, and Germany's Commission E has long recognised its therapeutic value.
German Chamomile is a slender annual herb growing 20–50 cm in height, with erect, highly branched stems bearing finely divided, aromatic leaves. The plant produces composite flower heads (capitula) featuring white ray florets surrounding a hollow, conical yellow disc — a morphological detail that distinguishes it from Roman chamomile, whose receptacle is solid.
It thrives in disturbed ground, roadsides, and uncultivated fields, and is particularly abundant across Central Europe and North Africa. It has been extensively cultivated in Germany, Hungary, Egypt, and Argentina for pharmaceutical and cosmetic use, with essential oil composition varying significantly by geographic origin and climatic conditions.
Etymology
The genus name derives from the Greek khamaimêlon ("ground apple"), referring to the pleasant green-apple scent of its foliage. The species epithet matricaria derives from Latin matrix (womb), reflecting its longstanding use in menstrual and obstetric disorders.
Identification Note
German Chamomile (Matricaria chamomilla) is frequently confused with Roman Chamomile (Chamaemelum nobile). The key distinguishing feature is the receptacle: hollow and conical in M. chamomilla, solid and flat in C. nobile. Their essential oil compositions and pharmacological profiles differ substantially.
German Chamomile has been a cornerstone of European herbal medicine for millennia, used across diverse cultures for its digestive, gynaecological, and wound-healing properties. Its name "German Chamomile" reflects the particular esteem in which it was held by Central European populations where it grows most abundantly.
Known as khamaimêlon by the ancient Greeks, chamomile was described in the works of Dioscorides and used for fevers, urinary complaints, and liver conditions. Roman physicians employed it for its calming and digestive properties.
Medieval herbalists classified chamomile as a matrix herb — for the womb — prescribing it for menstrual irregularities, labour pains, and childbirth. This tradition is preserved in the botanical name matricaria.
Chamomile tea became ubiquitous in Central European domestic medicine for colic, gastritis, anxiety, and insomnia. Germany became the centre of both cultivation and pharmacological interest, yielding its popular designation as "German Chamomile."
Germany's Commission E approved chamomile for gastrointestinal spasms and inflammatory GI diseases. The EMA published a comprehensive positive assessment report in 2015 covering both the flower and its essential oil.
Iranian Folk Medicine
"Topical chamomile oil decocted in sesame oil has been used in traditional Iranian medicine for migraine headache relief, a hypothesis now supported by preclinical pharmacological investigation."
Zargaran et al., 2014 — Ref [58]
German Chamomile is recorded in traditional pharmacopoeias from ancient Egypt and Greece to Ayurveda and Middle Eastern folk medicine, reflecting a cross-cultural convergence on its therapeutic value that modern clinical research continues to validate.
The flower head (capitule) is the primary medicinal part; the essential oil distilled from it is also independently used in aromatherapy and topical applications.
The principal medicinal part, used as an infusion, tincture, or dry extract. The capitule is listed in the French Pharmacopoeia (Liste A) and is the basis for EMA-assessed oral dosage forms for gastrointestinal and anxiety indications.
Steam-distilled from the capitule, yielding a characteristic deep-blue oil due to chamazulene. Used topically for dermatological conditions, aromatically for psychostimulant and anti-allergic effects, and in combination preparations for GI and gynaecological indications.
Concentrated extracts standardised to apigenin content are used in clinical studies at 220–1500 mg per day. These have been evaluated in RCTs for generalised anxiety disorder and depression with documented efficacy.
Based on EMA/HMPC Assessment Report (2015) for oral infusion of flower heads. [1]
The capitule contains a complex mixture of sesquiterpenes, flavonoids, coumarins, and mucilages. The essential oil composition varies markedly by geographic origin and chemotype.
Benzodiazepine Receptor Ligand
Apigenin is a competitive ligand at central BZD receptors, producing anxiolytic effects without anticonvulsant or myorelaxant activity.
COX-2 Selective Inhibition
Apigenin-rich extract shows novel and selective COX-2 inhibitory activity with reduced GI side-effect profile versus non-selective NSAIDs. [6]
Aromatase Blockade
Apigenin blocks a key step in oestrogen biosynthesis in both cancer cells and normal high-oestrogen-synthetic tissues.
Anti-inflammatory Synergy
Apigenin and luteolin display anti-inflammatory and antispasmodic activity equivalent in topical models to indometacin, acting synergistically with bisabolol.
Selective inhibition of COX-2, reducing prostaglandin synthesis. Chamomile extract demonstrates novel COX-2 selectivity comparable to celecoxib in preclinical models. [6]
Systematic review confirms significant free radical scavenging activity. Chamazulene inhibits lipid peroxidation of arachidonic acid and blocks leukotriene B4 formation. [7]
Bisabolol and polyacetylenic spiro-ethers inhibit cAMP-phosphodiesterase, producing smooth muscle relaxation more potent than papaverine in isolated preparations. [10]
Chamomile extract potentiates the anti-inflammatory activity of diclofenac and indometacin in carrageenan-induced inflammation while reducing their gastric side effects. [8]
Chamomile tea has been reviewed for lipid-lowering bioactivity, with evidence of cholesterol-modulating effects relevant to cardiovascular risk reduction. [9]
Multiple preclinical studies demonstrate significant analgesic activity in both acute and chronic pain models, in the presence and absence of sex hormones. [11][12][13][14][15]
Bisabolol protects against ethanol- and indometacin-induced gastric lesions via prostaglandin, nitric oxide, and KATP channel pathways. Also inhibits gastric acid production and H. pylori urease. [16][17][19][20][21]
Chamomile decoction exhibits antidiarrhoeal and antioxidant effects in rat models, attributed to tannin and flavonoid content and spasmolytic activity on intestinal smooth muscle. [23]
Methanolic extract inhibits mast cell-mediated allergy. Single oral administration demonstrates antipruritic activity with additive effects combined with antiallergic agents. [24][25]
Double-blind RCTs confirm significant reduction of GAD symptoms. Apigenin is a competitive BZD receptor ligand without anticonvulsant or myorelaxant effects. Long-term use (26 weeks) shows sustained benefit. [27][28][29]
1500 mg/day over 8 weeks demonstrated antidepressant effect in subjects with comorbid anxiety and depression. Exploratory RCTs support 220 mg 1–5× daily. [30][31]
Randomised placebo-controlled pilot study found standardised extract provides modest improvements in sleep latency and daytime function in chronic primary insomnia. [26]
Methanolic extract of Matricaria recutita shows protective activity against cerebral ischaemia/reperfusion injury in rat models. [33]
Chamomile extract demonstrates antiproliferative and apoptotic effects across multiple human cancer cell lines with minimal cytotoxicity toward normal cells — selectivity attributed primarily to apigenin. [34]
Spiro-ethers, bisabolol, and coumarins confer bactericidal and fungicidal activity. Oil macerate inhibits Helicobacter pylori urease production. [22]
Chamazulene with matricine and bisabolol provides powerful anti-phlogistic and antipruritic activity through inhibition of arachidonic acid peroxidation and leukotriene synthesis.
Traditional and clinically validated use for intestinal gas, dyspepsia, and gastric cramping. Double-blind multicenter RCT confirmed efficacy in functional dyspepsia. [49]
Modulates endometrial prostaglandin and leukotriene production, reducing menstrual bleeding and dysmenorrhoea. Multiple RCTs confirm efficacy comparable to mefenamic acid. [52], 53, 55
Apigenin and luteolin modulate AMPK, NF-κB, Nrf2, and PPARγ signalling pathways, indicating activity relevant to obesity and metabolic syndrome management. [50]
Topical bisabolol enhances trans-cutaneous absorption of poorly absorbed drugs, making chamomile a useful excipient for transdermal formulations alongside its own anti-inflammatory activity.
Chamomile flavonoids demonstrate antimutagenic activity in cell-based assays, potentially relevant to chemoprevention through reduction of DNA-damaging oxidative stress.
A multi-herb combination including M. chamomilla reduced asthmatic recurrences and rhinitis-related nocturnal waking in children. [51]
A 2022 phytochemical study found M. recutita roots to be a rich source of antioxidants and antibacterial compounds, suggesting value beyond the flower head. [35]
The deep-blue essential oil displays pharmacological activities that complement and extend those of the whole flower, with specific activity in dermatology, pain, and microbiology.
Chamomile EO and bisabolol oxide-rich fractions demonstrate significant anti-inflammatory and antiedematous activity. Bisabolol oxide A exhibits antihyperalgesic activity via peripheral mechanisms. [36][37]
EO produces antispasmodic effects predominantly through activation of potassium channels — a mechanism complementary to the cAMP-phosphodiesterase inhibition of the whole-plant extract. [41][42]
German chamomile EO shows anti-allergic activity. Chamazulene, the characteristic blue sesquiterpene, is identified as the primary anti-allergic constituent. [38][39][40]
Inhalation of chamomile EO in mice produces a psychostimulant profile — increasing locomotor activity and exploration — distinct from the anxiolytic effects of oral aqueous extract. [44]
Chamomile EO inhibits urease production by Helicobacter pylori, one of the mechanisms underlying its gastroprotective action in H. pylori-associated gastritis. [45]
Chamomile EO demonstrates activity against Herpes simplex virus, including strains resistant to acyclovir, suggesting potential as a topical antiviral agent. [46]
Chamomile EO displays activity against Anisakis larvae responsible for anisakiasis, a zoonosis from consumption of raw seafood. [47]
Azulenes in chamomile EO stimulate hepatic regeneration in rat liver models, attributed to the sesquiterpene azulene fraction. [48]
Topical application of chamomile oil improved bowel activity after caesarean section in a randomised controlled trial, indicating pro-kinetic activity via transdermal absorption. [43]
The essential oil promotes wound healing and tissue regeneration, attributed to bisabolol's anti-inflammatory and skin-penetration properties combined with the antibacterial activity of spiro-ethers.
Indications span gastrointestinal, neurological, gynaecological, dermatological, and respiratory domains, supported by regulatory assessments, RCTs, and systematic reviews.
Multiple parallel mechanisms underlie German Chamomile's broad therapeutic profile, with synergistic interactions between constituent classes.
Chamomile extract selectively inhibits COX-2, reducing prostaglandin synthesis. Beyond COX-2, it suppresses synthesis and release of prostaglandins, leukotrienes, bradykinin, histamine, and serotonin — a multi-target anti-inflammatory profile. [6]
Bisabolol and polyacetylenic spiro-ethers inhibit human cAMP-phosphodiesterase, elevating intracellular cAMP and relaxing smooth muscle. This spasmolytic activity surpasses papaverine in isolated preparations. [10]
Aqueous chamomile extracts bind central benzodiazepine receptors. Apigenin is a competitive ligand, producing anxiolytic effects without the anticonvulsant or myorelaxant effects of classical benzodiazepines. [27]
The essential oil mediates antispasmodic and antidiarrhoeal effects predominantly through K⁺ channel activation — distinct from and complementary to the cAMP-PDE inhibition of whole-plant extracts. [41]
Chamazulene inhibits leukotriene B4 formation and blocks peroxidation of arachidonic acid, acting as both anti-inflammatory and antioxidant. It is also potently anti-allergic and antibacterial. [40]
Apigenin blocks a key step in the oestrogen biosynthetic pathway in both cancer cells and normal high-oestrogen-synthetic tissues, underlying utility in hormonally driven gynaecological conditions. [34]
EO constituents — chamazulene, cis-spiroether, trans-spiroether — inhibit CYP1A2 and to a lesser degree CYP3A4. Chamazulene and bisabolol also inhibit CYP2D6, raising clinically relevant drug interaction concerns at high EO doses. [61]
Pour 150–200 ml of boiling water over 1.5–4 g of dried flower heads. Steep covered for 10 minutes. Strain and drink warm. Dose: 3–4 cups daily for adults (EMA). [1]
Hydroalcoholic tincture of the whole plant for oral use. Prepared to standard pharmacopoeial methods; used as a digestive, antispasmodic, and anxiolytic in integrative medicine.
Steam distillation of flower heads. Used topically (diluted 1–3% in carrier oil) for dermatological and anti-inflammatory applications, and by inhalation for psychostimulant and anti-allergic effects. [1]
Standardised liquid extract for compound preparations; used in licensed traditional herbal medicinal products across Europe combining with other antispasmodic or digestive herbs.
The capitule of Matricaria chamomilla is listed in the French Pharmacopoeia, Liste A, recognising established medicinal use in France.
Germany's Commission E formally recognises therapeutic activity for internal use (GI spasms, inflammatory GI diseases) and external use (skin and mucosal inflammation).
The EMA's HMPC published a positive assessment report for Matricaria recutita L. flos and essential oil in July 2015 (EMA/HMPC/55837/2011), establishing well-established and traditional use categories. [1]
Chamomile preparations meeting pharmacopoeial standards qualify for registration as Traditional Herbal Medicinal Products under EU Directive 2004/24/EC across Member States.
German Chamomile has a well-established safety profile; the main concerns relate to Asteraceae hypersensitivity, coumarin-mediated allergic reactions, and CYP-based drug interactions at high essential oil doses.